6-溴异吲哚啉-1-酮 | 675109-26-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 6-溴异吲哚啉-1-酮
• 中文别名: 6-溴-1-异吲哚酮；6-溴-2,3-二氢-1H-异吲哚-1-酮
• 英文名称: 6-bromoisoindolin-1-one
• 英文别名: 6-bromo-2,3-dihydroisoindol-1-one；6-bromo-2,3-dihydro-1H-isoindol-1-one
• CAS: 675109-26-9
• 化学式: C₈H₆BrNO
• mdl: MFCD11848599
• 分子量: 212.046
• InChiKey: HYTCKZQYVIURAW-UHFFFAOYSA-N

物化性质

• 沸点：
  431.7±45.0 °C(Predicted)
• 密度：
  1.666±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933790090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温下密封保存，并确保环境干燥。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Bromoisoindolin-1-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromoisoindolin-1-one
CAS number: 675109-26-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H6BrNO
Molecular weight: 212.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-溴异吲哚啉-1-酮 在 硼烷四氢呋喃络合物 、 盐酸 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 14.0h， 生成 5-溴异二氢吲哚盐酸盐
  参考文献：
  名称：

  一种5-溴异二氢吲哚盐酸盐的制备方法

  摘要：

  本发明提供了一种5‑溴异二氢吲哚盐酸盐的制备方法，从5‑溴‑2‑甲基苯甲酸出发，先酯化，然后甲基NBS溴代，关环，再硼烷还原得到所述5‑溴异二氢吲哚盐酸盐，路线简单，不产生大量废酸废水，每个步骤易于操作，收率高。

  公开号：

  CN107474006A
• 作为产物：
  描述：

  5-溴-2-溴甲苯甲酸甲酯 在 氨 作用下， 以 甲醇 为溶剂， 反应 24.0h， 以87%的产率得到6-溴异吲哚啉-1-酮
  参考文献：
  名称：

  含有N-BOH部分的可调谐高荧光BN-1,2-氮杂嘌呤衍生物的合成，计算和光谱分析†

  摘要：

  使用便利的两步一锅法合成了九个含有N-BOH部分的新的多环芳香族BN-1，2-氮杂硼啉类似物。所制备化合物的表征显示出发光波长，并且通过控制发色团上的供体和受体取代基的功率和位置，可调节氮杂硼烷的量子产率。紫外可见光谱法和密度泛函理论（DFT）计算表明，在异吲哚满酮半球中添加给电子部分增加了HOMO的能量，从而减少了HOMO-LUMO间隙。在异吲哚啉酮半球中增加了一个电子接受基团，在硼酸半球中增加了一个供电子基团，从而大大降低了HOMO-LUMO间隙。导致部分分子内电荷转移（ICT）状态的发射特性。异吲哚啉酮侧的受体和硼酸侧的供体（强受体–π-供体）的综合作用产生了最大的红移吸收。多环芳族BN-1,2-氮杂嘌呤在溶液中和固态时发出强荧光，在640 nm处的红移最大，斯托克斯位移为Δλ＝ 218nm，或Δν＝ 8070cm -1。

  DOI：

  10.1039/c7ob02415k

文献信息

• METALLO-BETA-LACTAMASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20160333021A1

  公开（公告）日：2016-11-17

  The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

  本发明涉及式(I)的化合物，这些化合物是金属β-内酰胺酶抑制剂，以及这些化合物的合成和与β-内酰胺类抗生素一起用于克服耐药性的用途。
• ASK1 ISOINDOLIN-1-ONE INHIBITORS AND METHODS OF USE THEREOF
  申请人：Hepatikos Therapeutics, LLC

  公开号：US20200002312A1

  公开（公告）日：2020-01-02

  Isoindolin-1-one compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoindolin-1-one compound or analogs thereof, in the treatment of disorders characterized by the activation of ASK1 (e.g., cardiovascular diseases, inflammatory disorders (acute or chronic), autoimmune diseases, destructive bone disorders, fibrotic diseases/disorders such as alcoholic steatohepatitis; non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH), neurodegenerative disorders, and metabolic diseases such as diabetes).

  披露了用于治疗各种疾病和病理的异吲哚啉-1-酮化合物。更具体地说，本公开涉及使用异吲哚啉-1-酮化合物或其类似物，在治疗由ASK1激活表征的疾病中的应用，例如心血管疾病、炎症性疾病（急性或慢性）、自身免疫疾病、破坏性骨病、纤维化疾病/障碍，如酒精性脂肪肝炎；非酒精性脂肪肝疾病（NAFLD）；非酒精性脂肪肝炎（NASH）、神经退行性疾病，以及如糖尿病之类的代谢性疾病。
• [EN] GLYCOSIDASE INHIBITORS<br/>[FR] INHIBITEURS DE GLYCOSIDASES
  申请人：ASCENEURON S A

  公开号：WO2017144633A1

  公开（公告）日：2017-08-31

  Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

  式(I)中A、R、W、Q、n和m的含义如权利要求书所述，可用于治疗tau病和阿尔茨海默病。
• Comprehensive structure-activity-relationship of azaindoles as highly potent FLT3 inhibitors
  作者：Sebastian H. Grimm、Berend Gagestein、Jordi F. Keijzer、Nora Liu、Ruud H. Wijdeven、Eelke B. Lenselink、Adriaan W. Tuin、Adrianus M.C.H. van den Nieuwendijk、Gerard J.P. van Westen、Constant A.A. van Boeckel、Herman S. Overkleeft、Jacques Neefjes、Mario van der Stelt

  DOI：10.1016/j.bmc.2019.01.006

  日期：2019.3

  Acute myeloid leukemia (AML) is characterized by fast progression and low survival rates, in which Fms-like tyrosine kinase 3 (FLT3) receptor mutations have been identified as a driver mutation in cancer progression in a subgroup of AML patients. Clinical trials have shown emergence of drug resistant mutants, emphasizing the ongoing need for new chemical matter to enable the treatment of this disease

  急性髓细胞性白血病（AML）的特征是进展快，生存率低，其中已将Fms样酪氨酸激酶3（FLT3）受体突变确定为AML患者亚组中癌症进展的驱动程序突变。临床试验已显示出耐药突变体的出现，强调了对新化学物质的持续需求，以使该疾病得以治疗。在这里，我们介绍了已知的PKA抑制剂异喹啉磺酰胺H-89作为FLT3抑制剂的类似物的发现和拓扑结构-活性关系（SAR）研究。令人惊讶地，我们发现SAR与在PKA中观察到的H-89的结合模式不一致。匹配的分子对分析导致鉴定出高活性的亚纳摩尔氮杂吲哚作为新型的FLT3抑制剂。
• [EN] METALLO-BETA-LACTAMASE INHIBITORS<br/>[FR] INHIBITEURS DE MÉTALLO-BÊTA-LACTAMASES
  申请人：MERCK SHARP & DOHME

  公开号：WO2015112441A1

  公开（公告）日：2015-07-30

  The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

  本发明涉及式(I)的化合物，这些化合物是金属β-内酰胺酶抑制剂，以及这些化合物的合成和与β-内酰胺类抗生素一起用于克服耐药性的用途。